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cell line and aﬀects cellular autophagy and cell
cycle
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Ganoderma lucidum is one of the most extensively studied mushrooms as a functional food and as a
chemopreventive agent due to its recognized medicinal properties. Some G. lucidum extracts have
shown promising antitumor potential. In this study, the bioactive properties of various extracts of
G. lucidum, from both the fruiting body and the spores, were investigated. The most potent extract
identiﬁed was the methanolic fruiting body extract, which inhibited the growth of a gastric cancer cell
line (AGS) by interfering with cellular autophagy and cell cycle.1 Introduction
The exhaustive search for new ways of treating and preventing
cancer has led to the discovery of new drugs based on either
natural products or analogs inspired by them.1 Indeed,
although there is a lack of objective biological mechanistic
responses, some natural matrices have been investigated as a
source of anti-cancer agents and some encouraging ndings
have been identied.2,3
Mushrooms are examples of natural matrices which appear
to hold potential health benets, being recognized as functional
foods and as a source of compounds for the development of
nutraceuticals or medicines, including compounds with anti-
tumor properties.4 Medicinal mushrooms are generally well-
tolerated with few, if any, side eﬀects. Nevertheless, it is still not
completely well understood whether their vast bioactive eﬀects
are caused only by a single component or if they are the result of
an additive, or even synergistic outcome due to severalzar (ICBAS), University of Porto, Porto,
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hemistry 2014compounds. It is believed that these benets are mainly
attributed to their richness in polysaccharides (e.g., b-glucans),
the primary active immune-enhancing constituents.5,6
Ganoderma lucidum extracts and compounds have
demonstrated interesting advantages as adjuvants in the preven-
tion and treatment of cancer, possessing anti-proliferative or
growth inhibitory properties in various types of human tumor cell
lines such as the LNCaP cell line (prostate cancer),7 sarcoma 180
and Lewis lung carcinoma cell lines (lung cancer),8 monocytic
THP-1 cell line (acutemonocytic leukemia),9MCF-7 cell line (breast
cancer),10 andHUC-PC andMCT-11 cell lines (bladder cancer).11 As
a supplement during chemo- or radio-therapy, G. lucidum can
enhance curative eﬀects and reduce detrimental side-eﬀects
associated with this kind of treatment, such as fatigue, immuno-
suppression, anorexia, hair loss and bonemarrow suppression.12–15
Taking into consideration the enormous potential of this
mushroom and the fact that the underlying molecular mecha-
nisms of the bioactive metabolites are far from being fully
understood, the main goal of this work was to further investi-
gate the eﬀect of diﬀerent extracts of G. lucidum (from the
fruiting body and spores) on various human tumor cell lines. In
addition, the eﬀect of the most potent extract (methanolic
extract from the fruiting body) was further studied in the most
sensitive cell line, a gastric cancer cell line (AGS), by studying
the eﬀect on cellular proliferation, cell cycle prole, pro-
grammed cell death and autophagy.2 Experimental
2.1 Preparation of the Ganoderma lucidum extracts
Samples of Ganoderma lucidum (Curtis) P. Karst. were collected
in Bragança (Northeast Portugal) in July 2011. Aer taxonomicFood Funct., 2014, 5, 1389–1394 | 1389
Food & Function Paperidentication of the sporocarps,16–18 specimens were deposited
at the herbarium of Escola Superior Agra´ria of Instituto
Polite´cnico de Bragança under the number BRESA-gl01-2011.
The fruiting bodies were further separated from spores using a
scalpel, and all the samples were lyophilised and powdered
(20 mesh). Phenolic (methanolic and ethanolic) and poly-
saccharidic (boiling water) extracts were prepared from the
lyophilised powder following the procedure previously
described by us.19 The phenolic and polysaccharidic extracts
from the G. lucidum fruiting body and spores were chemically
characterized in a previous report.20 The extracts were kept in
DMSO and stored at 20 C.
2.2 Cell culture of human tumor cell lines
The following cell lines were used in this study: AGS (gastric
adenocarcinoma), MCF-7 (breast adenocarcinoma), NCI-H460
(non-small cell lung cancer) and HCT-15 (colorectal adenocar-
cinoma). Cells were routinely maintained in RPMI-1640
medium with Ultraglutamine I (Lonza) supplemented with 5%
or 10% (depending on the assay to be performed as explained
below) heat inactivated fetal bovine serum (FBS, PAA) at 37 C in
a humidied atmosphere containing 5% CO2. The cell number
and viability were assessed with trypan blue exclusion assay.
2.3 Primary culture of porcine liver cells
A cell culture was prepared from a freshly harvested porcine
liver obtained from a local slaughter house, and it was designed
as PLP2. Briey, the liver tissues were rinsed in Hank's balanced
salt solution containing 100 U ml1 penicillin, 100 mg ml1
streptomycin and divided into 1  1 mm3 explants. Some of
these explants were placed in 25 cm2 tissue asks in DMEM
supplemented with 10% fetal bovine serum, 2 mM nonessential
amino acids, 100 U ml1 penicillin, and 100 mg ml1 strepto-
mycin and incubated at 37 C in a humidied atmosphere
containing 5% CO2. The medium was changed every two days.
Cultivation of the cells was continued with direct monitoring
every two to three days using a phase contrast microscope.
Before conuence was reached, cells were subcultured and
plated in 96-well plates at a density of 1.0  104 cells per well,
and cultivated in DMEM with 10% FBS, 100 U ml1 penicillin
and 100 mg ml1 streptomycin.21
2.4 Screening for in vitro cell growth inhibition
Cell growth inhibition of tumor cell lines and of primary
porcine liver cells was studied with the sulforhodamine B (SRB)
assay. Tumor cells were plated in 96-well plates (7.5  103 cells
per well for AGS cells, 5  103 cells per well for MCF7 and NCI-
H460 cells and 1  104 cells per well for HCT-15 cells) and
incubated at 37 C for 24 h. Porcine liver cells were plated as
indicated above in Section 2.3. Exponentially growing cells were
then treated with 5 serial dilutions (1 : 2) of each extract
(ranging from 25 to 400 mg ml1). Following 48 h treatment,
cells were xed with 10% ice cold trichloroacetic acid, washed
with water and stained with SRB. Aer washing with 1% acetic
acid, bound SRB was solubilized with 10 mM Tris base and the
absorbance was measured at 510 nm using a microplate reader1390 | Food Funct., 2014, 5, 1389–1394(Biotek Instruments Inc. Synergy Mx, USA). For each extract, the
corresponding GI50 (concentration which inhibited 50% of net
cell growth) was determined, as previously described.22,23 The
eﬀect of the vehicle solvent (DMSO) on the growth of each cell
line was also analysed by treating cells with the maximum
concentration of DMSO used in each assay (0.4%).2.5 AGS cellular treatment with the G. lucidum methanolic
extract
AGS cells were plated at 1.5  105 cells per well in 6-well plates
(in RPMI-1640 medium with Ultraglutamine I supplemented
with 10% FBS) and incubated for 24 h. Cells were then treated
with complete medium (blank), with G. lucidum methanolic
fruiting body extract (106 mg ml1) or the equivalent volume of
the extract solvent (DMSO).
Following 48 h of treatment, cells were further processed as
indicated in the protocols below.
2.5.1 Cell proliferation analysis. Proliferation was analysed
with the BrdU incorporation assay. One hour before the 48 h
treatment, cells were incubated for 1 h with 10 mM BrdU
(Sigma). Cells were then xed in 4% paraformaldehyde (PFA) in
PBS. Cytospins were prepared and incubated in 2 M HCl for 20
min. Following incubation with mouse anti-BrdU (1 : 10, Dako),
cells were further incubated with the uorescein-labeled rabbit
anti-mouse antibody (1 : 100, Dako), as previously described.24
Slides were mounted in Vectashield Mounting Media with DAPI
(Vector Laboratories) and cells were observed using a DM2000
uorescence microscope (LEICA). A semi-quantitative evalua-
tion of the proliferation levels was done by counting a
minimum of 500 cells per slide.
2.5.2 Cell cycle prole analysis. Cells were xed in ice-cold
70% ethanol and kept at 4 C for at least 12 h. Prior to analysis,
cells were incubated with propidium iodide (5 mg mL1) and
RNase A in PBS (100 mg ml1) for 30 min on ice. The cellular
DNA content was analyzed using a FACS Calibur (BD Biosci-
ences) ow cytometer.25,26 Analysis of the cell cycle prole was
carried out using the FlowJo 7.6.5 soware (Tree Star, Inc.,
Ashland, OR, USA) aer cell debris and aggregate exclusion.
2.5.3 Apoptosis analysis. The levels of apoptosis were
analysed by ow cytometry using the Human Annexin V-FITC/PI
apoptosis kit (Bender MedSystems, Vienna, Austria), according
to the manufacturer's instructions. Flow cytometry was carried
out using a FACS Calibur (BD Biosciences) ow cytometer and
plotting at least 20 000 events per sample, as previously
described.27 Data were analysed using the FlowJo 7.6.5 soware
(Tree Star, Inc., Ashland, OR, USA).
2.5.4 Protein expression analysis. Cells were lysed in Win-
man's buﬀer (1% NP-40, 0.1 M Tris–HCl pH 8.0, 0.15 M NaCl
and 5 mM EDTA) with EDTA-free protease inhibitor cocktail
(Roche). The protein content was quantied with the DC Protein
Assay kit (BioRad). Protein lysates (20 mg) were electrophoresed
on 12% SDS–PAGE and transferred to a nitro-cellulose
membrane (GE Healthcare). Membranes were incubated with
the following primary antibodies: rabbit anti-VPS34 (1 : 1000,
cell signaling), rabbit beclin-1 (1 : 1000, cell signaling), rabbit
anti-light chain 3 B, LC3 (1 : 1000, cell signaling), goat anti-actinThis journal is © The Royal Society of Chemistry 2014
Paper Food & Functionantibody (1 : 2000, Santa Cruz Biotechnology) and with the
corresponding secondary antibody: donkey anti-goat IgG–HRP
(1 : 2000, Santa Cruz Biotechnology) or goat anti-mouse IgG–
HRP (1 : 2000, Santa Cruz Biotechnology). The signal was
detected using Amersham™ ECL Western Blotting Detection
Reagents (GE Healthcare), the Amersham Hyperlm ECL (GE
Healthcare) and the Kodak GBX developer and xer (Sigma), as
previously described.28
2.5.5 Visualization of autophagosomes. Cells were incu-
bated for 1 h with freshly prepared 50 mM mono-
dansylcadaverine (MDC, Biochemika) and xed in 4%
paraformaldehyde (PFA) in PBS. Cytopsins were prepared and
mounted in Vectashield Mounting Media with DAPI. Cells were
then observed using a uorescence microscope (Axio Imager.Z1
coupled with ApoTome Imaging System microscope, Zeiss) for
the observation of autophagosomes, as previously described.29
2.6 Statistical analysis
Statistical signicance was determined with a two tailed Stu-
dent's t-test, except for the data presented in Table 2 in which
the unpaired Student's t-test was used. * indicates p < 0.05.
3 Results and discussion
3.1 Eﬀect of the diﬀerent G. lucidum extracts on the in vitro
growth of human tumor cell lines
It is known that the use of diﬀerent fractions of G. lucidum may
have diﬀerent outcomes in disease treatments.30 Therefore, in
this study, diﬀerent G. lucidum extracts, obtained from the
spores or from the fruiting body of this mushroom, were eval-
uated regarding their eﬀect on the in vitro growth of four human
tumor cell lines: AGS (gastric adenocarcinoma), MCF-7 (breast
adenocarcinoma), NCI-H460 (non-small cell lung cancer) and
HCT-15 (colorectal adenocarcinoma). This was carried out
using the sulforhodamine B (SRB) assay which quanties
protein thereby allowing us to indirectly assess cell growth22,31
and to determine the GI50 concentration of the extracts (corre-
sponding to the concentration that inhibits 50% of net cell
growth).
Results (Table 1) showed that polysaccharidic extracts from
G. lucidum presented no cytotoxic activity since all of them
presented GI50 higher than 400 mg ml
1 (for all of the cell linesTable 1 GI50 concentrations of various extracts from the fruiting body o
NC
Fruiting body Phenolic extract (methanolic) 107.
Phenolic extract (ethanolic)
Polysaccharidic extract (boiling water)
Spores Phenolic extract (methanolic) 386.
Phenolic extract (ethanolic)
Polysaccharidic extract (boiling water)
a Results are the mean SE of 3 independent experiments. Values >400 ind
to 400 mg ml1 (maximum concentration tested).
This journal is © The Royal Society of Chemistry 2014studied). The mentioned extracts were previously characterized
by the authors, being detected, aer polysaccharides hydrolysis,
the same sugars in the fruiting body and spore extracts: fructose
(0.65 and 2.15 g per 100 g dry weight, respectively), glucose
(0.55 and 0.83 g per 100 g), mannitol (7.36 and 8.24 g per 100 g)
and trehalose (2.76 and 3.27 g per 100 g) in the fruiting body
extract.20
On the other hand, the phenolic extracts (methanolic) from
both the fruiting body and the spores showed in vitro cell growth
inhibitory activity, particularly the one from the fruiting body,
which was the most potent extract in all cell lines studied. The
mentioned extract contains p-hydroxybenzoic acid (0.58 mg per
100 g dry weight), p-coumaric acid (0.38 mg per 100 g) and
cinnamic acid (0.28 mg per 100 g), as previously reported by the
authors.20 The higher activity revealed by the extract obtained
from the fruiting body might be related to its higher phenolic
compounds content in comparison with the extract prepared
from spores that included only p-coumaric (0.28 mg per 100 g)
and cinnamic (0.33 mg per 100 g) acids.
Regarding the phenolic extract (methanolic) from the spores,
diﬀerent eﬀects were observed depending on the cell lines
analyzed. This extract was more potent in the HCT15 cells fol-
lowed by NCI-H460 cells, but showed no cytotoxic eﬀect in the
other two cell lines studied (MCF-7 and AGS), presenting a GI50
concentration higher than the maximum concentration tested
(400 mg ml1). This may indicate that the mechanisms of action
of this extract aremore relevant in the HCT15 and NCI-H460 cell
lines than in the MCF-7 and AGS cells, possibly due to the
diﬀerent genetic background of those human tumour cell
models. However, the GI50 concentrations determined for the
methanolic extract of the spores were considered high and
therefore this extract was not further studied in the present
work.
The fact that the phenolic (methanolic) extract showed
cytotoxic towards human tumor cells is in agreement with
what has been previously published.32 Furthermore, up to
400 mg ml1, the evaluated extracts did not show cytotoxicity
against the primary culture of porcine liver cells, PLP2.
The most potent extract against tumor cell lines, the meth-
anolic extract from the G. lucidum fruiting body, was chosen to
be further studied regarding its eﬀect in cellular proliferation,
cell cycle prole and cell death. For this, AGS cells were analyzedr spores of G. lucidum in four human tumor cell linesa
GI50 (mg ml
1)
I-H460 HCT-15 MCF-7 AGS
5  5.3 103.4  13.2 112.6  6.7 93.3  9.1
>400 >400 >400 >400
>400 >400 >400 >400
9  11.15 280.8  11.17 >400 >400
>400 >400 >400 >400
>400 >400 >400 >400
icate that the GI50 concentration was not found when testing extracts up
Food Funct., 2014, 5, 1389–1394 | 1391
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(methanolic) of the fruiting body, hereaer referred to as
“G. lucidum methanolic fruiting body extract”.
3.2 Eﬀect of the G. lucidum methanolic fruiting body extract
in AGS cellular proliferation and cell cycle prole
Prompted by the eﬀect found on cell growth, it was intended to
investigate whether the eﬀect was due to alterations in cellular
proliferation. Therefore, the eﬀect of the G. lucidum extract on
AGS proliferation was analyzed by determining the percentage
of BrdU-incorporating cells following 48 h treatment (Fig. 1).
Results showed a decrease on the proliferation levels of AGS
cells (from 36% in blank and from 35% in DMSO) to approxi-
mately 19%, following treatment with the G. lucidum extract
(Fig. 1).
In addition, possible alterations in the cycle prole were
investigated by ow cytometry following PI labeling of the cells.
Results (Fig. 2) showed that the G. lucidum extract caused a
statistically signicant increase in the percentage of AGS cells in
the G1-phase of the cell cycle, together with a decrease in theFig. 1 Eﬀect of G. lucidum methanolic fruiting body extract on AGS
cellular proliferation. Cells were treated for 48 h with complete
medium (blank), G. lucidum extract or with the corresponding vehicle
(DMSO, control). Results are the mean  SE of three independent
experiments.
Fig. 2 Eﬀect of G. lucidum methanolic fruiting body extract on the
AGS cell cycle proﬁle. Cells were treated for 48 h with medium (blank),
G. lucidum extract or with the corresponding vehicle (DMSO, control).
Results are the mean  SE of 3 independent experiments. * indicates
p# 0.05 between treatment with the extract and with DMSO (control).
1392 | Food Funct., 2014, 5, 1389–1394percentage of cells in the G2-phase of the cell cycle. Moreover a
decrease in the S-phase was observed, although this was not
considered statistically signicant.
Other authors had previously reported a G1 cell cycle arrest
in breast cancer (MCF-7) cells treated with G. lucidum extracts.333.3 Eﬀect of the G. lucidum methanolic fruiting body extract
in programmed cell death
The fact that no alteration in the sub-G1 peak was previously
observed in the cell cycle analysis of AGS cells following treat-
ment with the extract suggested that its mechanism of action
did not involve apoptosis. Nevertheless, other studies have
indicated that some G. lucidum extracts (such as unboiled
aqueous extract and a methanol-extracted column-chromatog-
raphy semipuried fraction) induced apoptosis.34 Likewise, an
ethanolic fraction of G. lucidum was shown to induce apoptosis
in AGS cells, not only via the intrinsic mitochondrial pathway
but also through the death receptor-mediated extrinsic
apoptotic pathway.35
Therefore, it was further conrmed that the methanolic
extract from the fruiting body of G. lucidum induced pro-
grammed cell death, by analyzing the levels of apoptosis by ow
cytometry following Annexin V/PI labeling, which is an
apoptosis-specic assay. Results (Table 2) showed no alterations
in the levels of apoptosis following treatment with this extract.
This is possibly due to the concentrations and time points
tested in the present study. Indeed, in the previously mentioned
study of Calvino and collaborators, the concentrations tested
were far superior and the time points were inferior to the ones
tested in the present study.343.4 Eﬀect of the G. lucidum methanolic fruiting body extract
in autophagy
It has been suggested that G. lucidum associates with autoph-
agy.36–38 In fact, treatment with a triterpene extract from G.
lucidum suppressed the proliferation of HT-29 colon cancer cells
and inhibited the growth of the respective xenogra tumor
model. This eﬀect was shown to be due to the induction of
autophagy, with the extract inducing the formation of auto-
phagic vacuoles and upregulating the expression of autophagy-
associated proteins, such as beclin-1 and LC-3, both in HT-29
colon cancer cells as well as in the xenogra tumors.36 Recently,
G. lucidum was also shown to induce autophagy in a breast
cancer cell line, promoting the cell death.37
Therefore, in this study, in order to conrm whether the
extract interfered with cellular autophagy, the expression levelsTable 2 Levels of apoptosis of AGS cells following treatment with the
G. lucidum methanolic fruiting body extracta
Apoptotic cells (%)
Blank 7.9  1.1
DMSO 5.9  1.1
Extract 9.5  3.2
a Results are the mean  SE of 3 independent experiments.
This journal is © The Royal Society of Chemistry 2014
Fig. 3 Expression of autophagy- and apoptosis-related proteins in AGS cells following 48 h treatment with G. lucidummethanolic fruiting body
extract. (A) Western Blot images representative of at least 3 independent experiments. Actin was used as a loading control. (B) Densitometry
analysis of the Western blots. Results are the mean  SE of three independent experiments and are expressed after normalization of the values
obtained for each protein with the values obtained for actin and further expressed in relation to control cells. * indicates p < 0.05 between
treatment with the extract and with DMSO (control).
Fig. 4 Analysis of the eﬀect of the G. lucidum methanolic fruiting body extract in the presence of autophagosomes. Fluorescence microscopy
images after MDC incorporation (green) are representative of 2 independent experiments. Cell nuclei are stained with DAPI (blue). Bar corre-
sponds to 20 mm.
Paper Food & Functionof some autophagic proteins were analysed. Results (Fig. 3)
showed no alterations in the levels of VSP-34 and beclin-1.
However, a clear increase in the autophagy marker LC3-II was
evident in AGS cells treated with the extract. As expected, there
were no alterations in the Bcl-2 (antiapoptotic) protein levels
when cells treated with the extract were compared with control
(DMSO treated) cells.
This interference with cellular autophagy was further
conrmed by an increase in the monodansylcadaverine (MDC)
labeling of autophagosomes, observed in AGS cells following
treatment with the extract (Fig. 4).4 Conclusion
In summary, the G. lucidum methanolic fruiting body extract
inhibits the growth of a human gastric cancer cell line (AGS) by
interfering with cellular autophagy and cell cycle. Further
studies of the cellular and molecular mechanisms involved will
be pursued in future work.Conﬂict of interest
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